Arcturus Therapeutics Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics or view top-rated stocks.

Wall Street analysts have given Arcturus Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcturus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Arcturus Therapeutics.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings data on Sunday, May, 9th. The biotechnology company reported ($2.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by $0.90. Arcturus Therapeutics had a negative net margin of 506.70% and a negative trailing twelve-month return on equity of 52.32%.
View Arcturus Therapeutics' earnings history.

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARCT stock has increased by 119.6% and is now trading at $28.75.
View which stocks have been most impacted by COVID-19.

11 analysts have issued 1-year price targets for Arcturus Therapeutics' shares. Their forecasts range from $23.00 to $133.00. On average, they expect Arcturus Therapeutics' stock price to reach $68.58 in the next twelve months. This suggests a possible upside of 138.6% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics or view top-rated stocks among Wall Street analysts.

9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees.

Some companies that are related to Arcturus Therapeutics include Intra-Cellular Therapies (ITCI), Reata Pharmaceuticals (RETA), InnovAge (INNV), Taro Pharmaceutical Industries (TARO), MorphoSys (MOR), Pacira BioSciences (PCRX), Insmed (INSM), PTC Therapeutics (PTCT), Rocket Pharmaceuticals (RCKT), Corcept Therapeutics (CORT), Prestige Consumer Healthcare (PBH), Amicus Therapeutics (FOLD), OPKO Health (OPK), Xencor (XNCR) and Cryoport (CYRX).
View all of ARCT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY).

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.66%), Federated Hermes Inc. (12.17%), BlackRock Inc. (6.66%), Bank Julius Baer & Co. Ltd Zurich (1.58%), Geode Capital Management LLC (1.35%) and Sumitomo Mitsui Trust Holdings Inc. (1.20%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends for Arcturus Therapeutics.

ARCT stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, ARK Investment Management LLC, Federated Hermes Inc., Goldman Sachs Group Inc., Northern Trust Corp, Barclays PLC, Credit Suisse AG, and BlackRock Inc.. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc.
View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks.

ARCT stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Renaissance Technologies LLC, Clarus Group Inc., Clarus Group Inc., JPMorgan Chase & Co., Bank Julius Baer & Co. Ltd Zurich, Citigroup Inc., and Rafferty Asset Management LLC. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell.
View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARCT stock can currently be purchased for approximately $28.75.

Arcturus Therapeutics has a market capitalization of $756.70 million and generates $20.79 million in revenue each year. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

Arcturus Therapeutics employs 118 workers across the globe.

The official website for Arcturus Therapeutics is www.arcturusrx.com.

Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]